Successful treatment with reduced-intensity stem cell transplantation for secondary myelofibrosis following polycythemia vera.

Abstract

Ten years after being diagnosed with polycythemia vera, a 55-year-old woman required frequent blood transfusion due to secondary myelofibrosis. She underwent reduced-intensity stem cell transplantation (RIST) from an HLA-identical sibling donor. Since mixed chimerae were identified in the peripheral blood at day 35, cyclosporine was withdrawn. At day 73, she developed acute graft-versus-host disease of the liver, while simultaneous resolution of splenomegaly occurred and complete donor chimerism in the peripheral blood was achieved. Frequent red blood cell transfusion was required until day 300 after transplantation. Thus, RIST for an older patient with secondary myelofibrosis was successful without severe treatment-related morbidity. This case suggests that RIST could be an effective treatment modality for secondary myelofibrosis.

• Authors: Kenichi TAHARA, Akihiko YOKOHAMA, Hiroshi HANDA, Takayuki SAITOH, Hideki UCHIUMI, Tomomi SEKIGAMI, Kohtaro TOYAMA, Momoko MAWATARI, Yohei OSAKI, Takafumi MATSUSHIMA, Masamitsu KARASAWA, Hirokazu MURAKAMI, Norifumi TSUKAMOTO, Yoshihisa NOJIMA
• Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 50 Issue 11 Pg. 1630-4 (Nov 2009) ISSN: 0485-1439 [Print] Japan
• PMID: 20009439 (Publication Type: Case Reports, Journal Article)

Chemical References

• Janus Kinase 2
• Vidarabine
• fludarabine
• Melphalan

Topics

• Female
• Graft vs Host Disease (prevention & control)
• Humans
• Janus Kinase 2 (genetics)
• Melphalan (administration & dosage)
• Middle Aged
• Polycythemia Vera (complications)
• Primary Myelofibrosis (etiology, therapy)
• Stem Cell Transplantation
• Transplantation Conditioning
• Treatment Outcome
• Vidarabine (administration & dosage, analogs & derivatives)